While the present emphasis is on generating LAG3 antagonists for cancer immunotherapy that decrease inhibitory signaling, there is growing interest in developing LAG3 agonists to treat autoimmunity by increasing inhibitory signaling (26). Here, LAG3 is linked to cancer.